The nation could be one step closer to getting children protected against COVID-19.
Pharmaceutical company Pfizer filed a request with the FDA to amend its emergency use authorization to allow it to be used on children aged 12 to 15.
Currently, it’s allowed to be used by anyone age 16 and older.
“These requests are based on data from the pivotal Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection which demonstrated 100 percent efficacy and robust antibody response after vaccination with the COVID-19 vaccine,” the company said in a statement, CNN reported.
Pfizer, which partnered with BioNTech on the two-dose vaccine, will be issuing similar requests to other government regulating bodies around the world shortly, CNBC reported.
Pfizer started testing the vaccine in children as young as 9 last month and hopes to start vaccinating young children in early 2021. Moderna is also testing its vaccine on children 12 and older, as well as children 6 months to 12 years old, The New York Times reported last month.
More coronavirus pandemic coverage:
Cox Media Group